Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 8/20 | 0.54 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.54 |
| ▸ | DPP4 | P27487 | 5/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101956 | 0.90 | FOLH1 (0.52) | DPP7DPP9DPP8DPP4ACE | |
| SCHEMBL31679398 | 0.90 | ACE (0.56) | DPP7DPP9DPP8DPP4ACE | |
| SCHEMBL9052383 | 0.89 | DPP7 (0.53) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL2850058 | 0.88 | DPP7 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL29376792 | 0.88 | DPP7 (0.58) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL30954356 | 0.87 | DPP7 (0.54) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL29397354 | 0.87 | MME (0.54) | DPP7DPP9DPP8DPP4ACE | |
| SCHEMBL30833260 | 0.87 | DPP7 (0.57) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL8497101 | 0.87 | DPP7 (0.57) | DPP7DPP9DPP8DPP4SLC15A1 | |
| SCHEMBL31433356 | 0.86 | NOD1 (0.45) | DPP7DPP9DPP8DPP4ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746091-B | High-stability collagen targeting SERS polypeptide probe and application thereof in liver fibrosis diagnosis | 胶原蛋白(武汉)生物科技有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-115746091-A | High-stability collagen targeted SERS polypeptide probe and application thereof in hepatic fibrosis diagnosis | 胶原蛋白(武汉)生物科技有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | claimed |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2026-03-26 | — | — | US | disclosed |
| EP-4711004-A2 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | Rhythm Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | RHYTHM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4618952-A2 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | Rhythm Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-20250230483-A1 | OCULAR INSERTS WITH PROTEASE SENSING INDICATORS | TearDX LLC | 2025-07-17 | — | — | US | disclosed |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2025-06-19 | — | — | US | disclosed |
| CN-120152725-A | Methods of treating obesity using MC4R agonists | 节奏制药公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-114981310-A | Whole-process targeting molecule and application of drug compound thereof in construction of drug delivery system | 复旦大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-4029513-A1 | MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION | Rhythm Pharmaceuticals, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220195035-A1 | MONOCLONAL ANTIBODIES TO PROGASTRIN AND THEIR USES | LES LABORATOIRES SERVIER (FR) | 2022-06-23 | — | — | US | disclosed |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | IPSEN PHARMA SAS (FR) | 2022-04-28 | — | — | US | disclosed |
| EP-3988108-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR-ASSOCIATED DISORDERS IN HETEROZYGOUS CARRIERS | Rhythm Pharmaceuticals, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11299542-B2 | Monoclonal antibodies to progastrin and their uses | LES LABORATORIES SERVIER (FR) | 2022-04-12 | — | — | US | disclosed |
| WO-2022067086-A1 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | RHYTHM PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11273223-B2 | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles | HOFFMANN-LA ROCHE INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3960768-A1 | BISPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES | F. Hoffmann-La Roche AG (CH) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001915-A1 | METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST | MC4R, NPY4R, MC3R | DPP7 1818/4885DPP9 945/4885DPP8 1558/4885 |
| US-20260085092-A1 | MELANOCORTIN RECEPTOR LIGANDS | THRB, MC1R, MC5R | DPP7 513/4885DPP9 1005/4885DPP8 780/4885 |
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | DPP7 228/4885DPP9 462/4885DPP8 264/4885 |
| US-20250195606-A1 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | MC4R, MC5R, MC3R | DPP7 2314/4885DPP9 2171/4885DPP8 1811/4885 |
| US-20220127305-A1 | MELANOCORTIN RECEPTOR LIGANDS | MC3R, MC1R, MC5R | DPP7 2695/4885DPP9 2769/4885DPP8 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.